|
1
|
Lodhi SA, Lamb KE and Meier-Kriesche HU:
Solid organ allograft survival improvement in the United States:
The long-term does not mirror the dramatic short-term success. Am J
Transplant. 11:1226–1235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Collett D, Mumford L, Banner NR, Neuberger
J and Watson C: Comparison of the incidence of malignancy in
recipients of different types of organ: A UK Registry audit. Am J
Transplant. 10:1889–1896. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lanza LL, Wang L, Simon TA and Irish WD:
Epidemiologic critique of literature on post-transplant neoplasms
in solid organ transplantation. Clin Transplant. 23:582–588. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Engels EA, Pfeiffer RM, Fraumeni JF Jr,
Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly
AR, Clarke CA, et al: Spectrum of cancer risk among US solid organ
transplant recipients. JAMA. 306:1891–1901. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
vanLeeuwen MT, Webster AC, McCredie MRE,
Stewart JH, McDonald SP, Amin J, Kaldor JM, Chapman JR, Vajdic CM
and Grulich AE: Effect of reduced immunosuppression after kidney
transplant failure on risk of cancer: Population based
retrospective cohort study. BMJ. 340:c5702010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chiang YJ, Yang PS, Wang HH, Lin KJ, Liu
KL, Chu SH and Hsieh CY: Urothelial cancer after renal
transplantation: An update. Transplant Proc. 44:744–745. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang LJ, Wong YC and Huang CC: Urothelial
carcinoma of the native ureter in a kidney transplant recipient. J
Urol. 184:7282010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xiao J, Zhu X, Hao GY, Zhu YC, Hou HJ,
Zhang J, Ma LL, Tian Y and Zhang YH: Association between urothelial
carcinoma after kidney transplsantation and aristolochic acid
exposure: The potential role of aristolochic acid in HRas and TP53
gene mutations. Transplant Proc. 43:3751–3754. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang A, Shang D, Zhang J, Zhang L, Shi R,
Fu F and Tian Y: A retrospective review of patients with urothelial
cancer in 3,370 recipients after renal transplantation: a
single-center experience. World J Urol. 33:713–717. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Campistol JM, CuervasMons V, Manito N,
Almenar L, Arias M, Casafont F, Del Castillo D, Crespo-Leiro MG,
Delgado JF, Herrero JI, et al: ATOS Working Group: New concepts and
best practices for management of pre- and post-transplantation
cancer. Transplant Rev (Orlando). 26:261–279. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu GM, Fang Q, Ma HS, Sun G and Wang XC:
Distinguishing characteristics of urothelial carcinoma in kidney
transplant recipients between China and Western countries.
Transplant Proc. 45:2197–2202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meeks JJ, Bellmunt J, Bochner BH, Clarke
NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T,
et al: A systematic review of neoadjuvant and adjuvant chemotherapy
for muscle-invasive bladder cancer. Eur Urol. 62:523–533. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen AP, Setser A, Anadkat MJ, Cotliar J,
Olsen EA, Garden BC and Lacouture ME: Grading dermatologic adverse
events of cancer treatments: The Common Terminology Criteria for
Adverse Events Version 4.0. J Am Acad Dermatol. 67:1025–1039. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hou HJ, Xiao J and Tian Y: Contralateral
nephroureterectomy for renal transplant recipients with unilateral
upper urinary tract transitional cell carcinoma: A report of 12
cases. Transplant Proc. 45:2203–2206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schena FP, Pascoe MD, Alberu J, del Carmen
Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky
MS, Goldberg-Alberts R, et al: Sirolimus CONVERT Trial Study Group:
Conversion from calcineurin inhibitors to sirolimus maintenance
therapy in renal allograft recipients: 24-month efficacy and safety
results from the CONVERT trial. Transplantation. 87:233–242. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Geissler EK, Schlitt HJ and Thomas G:
mTOR, cancer and transplantation. Am J Transplant. 8:2212–2218.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leow JJ, MartinDoyle W, Rajagopal PS,
Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL,
Choueiri TK, et al: Adjuvant chemotherapy for invasive bladder
cancer: A 2013 updated systematic review and meta-analysis of
randomized trials. Eur Urol. 66:42–54. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leow JJ, MartinDoyle W, Fay AP, Choueiri
TK, Chang SL and Bellmunt J: A systematic review and meta-analysis
of adjuvant and neoadjuvant chemotherapy for upper tract urothelial
carcinoma. Eur Urol. 66:529–541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Culine S: Chemotherapy for advanced
transitional cell carcinoma of the urothelium: Cisplatin or
carboplatin? Eur Urol. 52:9–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dogliotti L, Cartenì G, Siena S, Bertetto
O, Martoni A, Bono A, Amadori D, Onat H and Marini L: Gemcitabine
plus cisplatin versus gemcitabine plus carboplatin as first-line
chemotherapy in advanced transitional cell carcinoma of the
urothelium: Results of a randomized phase 2 trial. Eur Urol.
52:134–141. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baitar A, De Vos M, Vandebroek A and
Schrijvers D: Carboplatin and gemcitabine in patients with advanced
and/or metastatic urothelial cancers: A phase II study. J Geriatr
Oncol. 2:31–35. 2011. View Article : Google Scholar
|
|
23
|
Mertens LS, Meijer RP, Kerst JM, Bergman
AM, van Tinteren H, van Rhijn BW and Horenblas S: Carboplatin based
induction chemotherapy for nonorgan confined bladder cancer - a
reasonable alternative for cisplatin unfit patients? J Urol.
188:1108–1113. 2012. View Article : Google Scholar : PubMed/NCBI
|
